Research Topics
| Mark Hyman RapaportSummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the artMark Hyman Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Clin Psychiatry 68:42-6. 2007..However, MAOIs have been well established as an effective intervention for people with treatment-resistant depression, and transdermal formulations may provide a valuable therapeutic option and eliminate the drug-food interaction...
Serial mitogen-stimulated cytokine production from continuously ill patients with schizophreniaMark H Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Neuropsychopharmacology 35:428-34. 2010..We conclude that continuously symptomatic medication-stabilized subjects with schizophrenia have a mitogen-stimulated cytokine expression pattern that is suggestive of ongoing immune activation...- Translating the evidence on atypical depression into clinical practiceMark Hyman Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center
J Clin Psychiatry 68:31-6. 2007..Although no tyramine-restricted diet is required for the 6-mg/24-hour patch, a restricted diet is recommended for the higher-dose patches to reduce the risk of hypertensive crisis... - Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuationMark Hyman Rapaport
Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Neuropsychopharmacology 31:2505-13. 2006..1 and 64.1%, respectively (p < or = 0.05). Open-label risperidone augmentation substantially enhanced response in treatment-resistant patients, but the longer-term benefits of augmentation were not demonstrated in this study... - The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placeboMark Hyman Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Psychiatr Res 45:931-41. 2011..MinD was not responsive to either a conventional antidepressant or a nutraceutical, and both compounds were associated with a notable side effects burden. Other treatment approaches for MinD should be investigated... - Celecoxib augmentation of continuously ill patients with schizophreniaMark Hyman Rapaport
Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles Department of Psychiatry, Geffen School of Medicine, University of California Los Angeles 90045, USA
Biol Psychiatry 57:1594-6. 2005..We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo... - Quality-of-life impairment in depressive and anxiety disordersMark Hyman Rapaport
Department of Psychiatry, Cedars Sinai Medical Center, Thalians Mental Health Center C 301, Los Angeles, CA 90048, USA
Am J Psychiatry 162:1171-8. 2005.... - Escitalopram continuation treatment prevents relapse of depressive episodesMark Hyman Rapaport
Department of Psychiatry, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Clin Psychiatry 65:44-9. 2004..Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment... - Efficacy of controlled-release paroxetine in the treatment of late-life depressionMark Hyman Rapaport
Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
J Clin Psychiatry 64:1065-74. 2003..Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition... - Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trialMark Hyman Rapaport
Department of Psychiatry, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
J Clin Psychiatry 70:46-57. 2009..To evaluate the efficacy and tolerability of low daily doses of controlled-release (CR) paroxetine in patients with late-life depression... - Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorderLewis L Judd
Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
Am J Psychiatry 161:1864-71. 2004..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder... - The effects of celecoxib augmentation on cytokine levels in schizophreniaCatherine J Bresee
Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles, CA 90045, USA
Int J Neuropsychopharmacol 9:343-8. 2006..These elevations did not persist by week 8. Overall, celecoxib does not significantly modify cytokine levels in medicated schizophrenia subjects... 
The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depressionWaguih William Ishak
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
Harv Rev Psychiatry 19:277-89. 2011..This review will examine the evidence for the impact of each modality, as well as their combination, on QOL in depression...- A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient settingWaguih William Ishak
Cedars Sinai Medical Center, 8730 Alden Drive, Thalians W 157, Los Angeles, CA 90048, USA
Qual Life Res 22:585-96. 2013..We performed a detailed analysis of the interaction between depressive symptom severity, functioning, and QOL in outpatients with MDD in order to better understand QOL impairments in MDD... - Clinical features and functioning of patients with minor depressionRobert H Howland
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Psychother Psychosom 77:384-9. 2008..The two essential features of minor depression are that it has fewer symptoms than major depression and that it is less chronic than dysthymia. This study describes the clinical features and functioning of outpatients with minor depression... - Quality of life: the ultimate outcome measure of interventions in major depressive disorderWaguih William Ishak
University of California, Los Angeles Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA 90048, USA
Harv Rev Psychiatry 19:229-39. 2011..Patients with major depressive disorder (MDD) have a significantly diminished QOL... - Translating the evidence on atypical depression into clinical practiceMark Hyman Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, USA
J Clin Psychiatry 68:e11. 2007..A newer MAOI, the transdermal formulation of selegiline, may provide all of the efficacy of the older MAOIs in treating atypical depression without causing as great of adverse events and no diet restrictions... - Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot studyAlexander Fan
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Bipolar Disord 14:206-10. 2012..Two previous inpatient trials demonstrated that allopurinol has anti-manic activity. Our objective was to test allopurinol as an adjunct to standard medications in bipolar disorder manic outpatients... - Studies characterizing 60 kda autoantibodies in subjects with schizophreniaXiao-Fen Wang
Department of Psychiatry, Veterans Affairs Medical Center, San Diego, California, USA
Biol Psychiatry 53:361-75. 2003..CONCLUSIONS: There is an increased prevalence of autoantibodies that bind to proteins migrating at 60 kDa in subjects with schizophrenia. Potential target antigens include HSP60 and PAM... - A descriptive analysis of minor depressionMark Hyman Rapaport
Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
Am J Psychiatry 159:637-43. 2002..The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder... - The role of dopaminergic agents in improving quality of life in major depressive disorderWaguih William Ishak
Department of Psychiatry, Cedars Sinai Medical Center and David Geffen School of Medicine at UCLA, 8730 Alden Drive, Thalians W 157, Los Angeles, CA 90048, USA
Curr Psychiatry Rep 11:503-8. 2009..Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings... - Beyond acute treatment of depressive disordersMark Hyman Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, USA
J Clin Psychiatry 70:e21. 2009..By continuously monitoring patients and making modifications when necessary, clinicians can help patients achieve and sustain remission... - Helping patients with depression achieve wellnessMark Hyman Rapaport
Department of Psychiatry and Behavioral Neurosciences, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, CA, USA
J Clin Psychiatry 70:e11. 2009..Strategies such as incorporating objective measures into clinical practice and collaborating with patients throughout therapy will increase the likelihood of attaining wellness... - Classification and treatment of sub-threshold depressionSarah K Rowe
Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90048, USA
Curr Opin Psychiatry 19:9-13. 2006.... - Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorderLev Gertsik
California Clinical Trials Medical Group, Glendale, CA 91206, USA
J Clin Psychopharmacol 32:61-4. 2012..We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response...